Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 5.09%, which has investors questioning if this is right time to sell.

Patients with both psoriasis and hidradenitis suppurativa had the highest overall psoriasis genetic risk score. The also had the highest overall non-human leukocyte antigen genetic risk score.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

“I am excited to take on the role as CFO as we launch and further commercialize ZORYVE in multiple inflammatory skin conditions and build upon our strong financial position,” said Vairavan. “Having ...

This agreement includes an extension of the 30-month Hatch-Waxman regulatory approval stay, providing Arcutis with continued market exclusivity for its psoriasis treatment, ZORYVE cream 0.3%. Analysts ...